01Purpose and principlesWhat the treatment does and how it fits into care.
The anti-inflammatory effect of tetracyclines helps widespread inflammatory acne, but antibiotic exposure also selects resistance in skin, gut and contacts. Stewardship begins before the first capsule: confirm that the eruption is acne, document sufficient inflammatory severity, choose one non-antibiotic topical partner and agree a finite decision point. Antibiotics do not correct microcomedone formation and therefore should never carry the regimen alone.
NICE first-line systemic choices are once-daily oral lymecycline or doxycycline combined for twelve weeks with fixed adapalene–benzoyl peroxide or with azelaic acid. Pregnancy potential, age, allergy, hepatic and renal factors, swallowing difficulty, photosensitivity, interacting medicines and previous courses influence selection. Give administration instructions for the exact product dispensed rather than generic advice that conflicts with its formulation.
At review, separate adherence, tolerability and diagnosis from biological response. Clear disease means the antibiotic stops while non-antibiotic topical prevention continues. Partial improvement can justify up to twelve more weeks; no meaningful response after correct use prompts a different NICE option or dermatology referral according to severity and treatment history. Repeating familiar prescriptions without a stop plan exposes the patient while allowing scars to accumulate.
When a tetracycline is unsuitable, do not improvise an unbounded substitute. NICE allows an oral macrolide such as erythromycin or trimethoprim to replace lymecycline or doxycycline in a combination, but selection should reflect pregnancy, allergy, interaction, local antimicrobial and specialist considerations and the thinner acne evidence base. The same twelve-week review discipline applies. In pregnancy, topical options are constrained and oral treatment warrants obstetric and dermatology-aware prescribing; neither trimethoprim nor a macrolide should be presented as a universally safe automatic swap.
Reconcile prescribing across services and online suppliers. A topical antibiotic may sit under a brand name, an expired doxycycline repeat can remain active, or isotretinoin may have started since the primary-care prescription. Ask about supplements containing vitamin A, antacids and minerals, and explain why antibiotic-free intervals are intentional rather than abandonment. If treatment stops early through nausea, swallowing pain, photosensitivity or access problems, record actual exposure in weeks; calling that an adequate failed course can misdirect referral and future prescribing. Conversely, an adherent course with new scarring should trigger prompt escalation even before a routine repeat cycle is completed.
Key points
- Reserve oral antibiotics for moderate-to-severe inflammatory acne; comedonal acne alone needs follicular topical therapy, not systemic antibacterial exposure.
- Pair oral lymecycline or doxycycline with adapalene–benzoyl peroxide or azelaic acid; never use an oral acne antibiotic alone.
- Do not combine an oral antibiotic with topical clindamycin or another topical antibiotic, because this adds resistance pressure without being a NICE regimen.
- Set a twelve-week review when prescribing: indication, companion topical, planned stop decision and safety advice should be visible in the record.
- If acne is clear at twelve weeks, stop the antibiotic and continue the topical; if improved but not clear, consider at most twelve further weeks before another review.
- Treatment continuing beyond six months should be exceptional, reviewed every three months and stopped as soon as possible.
- Tetracyclines are unsuitable in pregnancy, breastfeeding and children under 12, and must not overlap with isotretinoin because of intracranial-hypertension risk.
- Failure after an adherent oral-antibiotic-containing course in moderate-to-severe acne is a specialist referral criterion, not an invitation to cycle indefinite antibiotics.
- A later relapse does not automatically justify the same oral prescription: re-grade inflammation and scars, review maintenance use and reconsider specialist need before restarting antimicrobial exposure.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Numerous inflammatory papules and pustules, painful nodules or substantial truncal involvement can justify an oral antibiotic alongside topical therapy.
Predominantly open and closed comedones without meaningful inflammation are unlikely to benefit from systemic antibiotics and favour a topical retinoid mechanism.
New odynophagia, dysphagia or retrosternal pain during doxycycline therapy suggests pill oesophagitis and requires prompt review of the medicine and complications.
Persistent severe headache, pulsatile tinnitus, nausea, diplopia or visual obscurations during tetracycline exposure needs urgent assessment, particularly if isotretinoin has overlapped.
An exaggerated sunburn-like eruption on exposed skin after doxycycline supports a phototoxic reaction; prevention advice and regimen reassessment are required.
Repeated prescriptions with no documented lesion improvement, topical partner or stop date identify a stewardship failure even if no adverse event has occurred.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Clinical severity and scar baselineFirst step - Why
- Verify that expected systemic benefit justifies antibiotic exposure.
- Interpretation and limitations
- Record inflammatory lesion depth, sites and emerging scars; routine bacterial culture is not required for ordinary acne.
- 02
Pregnancy, age and feeding assessment - Why
- Exclude major tetracycline contraindications before prescribing.
- Interpretation and limitations
- Use a non-tetracycline NICE strategy in pregnancy, while trying to conceive, during breastfeeding or below 12 years; discuss uncertainty rather than assuming.
- 03
Full medicine and supplement reconciliation - Why
- Find oral or topical antibiotic duplication, isotretinoin overlap and absorption interactions.
- Interpretation and limitations
- Stop a topical antibiotic when starting the oral agent, never overlap isotretinoin, and give product-specific separation advice for antacids, iron, zinc or calcium.
- 04
Renal and hepatic assessment when indicated - Why
- Select and dose treatment safely in organ impairment or significant comorbidity.
- Interpretation and limitations
- Healthy patients do not need automatic broad blood panels for a routine course; investigate when history, examination or the chosen product requires it.
- 05
Twelve-week outcome review - Why
- Make the stop, short extension, switch or referral decision.
- Interpretation and limitations
- Judge active inflammation and new scarring against baseline, verify adherence and topical use, and do not count residual pigment alone as ongoing antibiotic-responsive disease.
04Treatment approachPreparation, options, escalation and aftercare.
01Start systemic treatmentBuild one finite combinationFirst stepModerate-to-severe inflammatory acne is confirmed and an oral tetracycline is appropriate.+
- 1Check pregnancy, breastfeeding, age, interactions, organ impairment, prior courses and scar trajectory, then select once-daily lymecycline or doxycycline.
- 2Pair it with fixed adapalene–benzoyl peroxide or azelaic acid, removing every topical antibiotic and explaining administration, photosensitivity and serious adverse symptoms.
- 3Prescribe an initial twelve-week course with the review date and intended stopping logic documented from the outset.
02Twelve-week decisionStop exposure when benefit permitsThe planned first systemic course reaches twelve weeks.+
- 1If clear, stop the oral antibiotic and maintain control with an appropriate non-antibiotic topical regimen.
- 2If meaningfully improved but not clear, consider continuing the oral agent with its topical partner for up to twelve further weeks, then reassess.
- 3If little response, verify diagnosis and use before changing strategy; moderate-to-severe acne after an adequate oral-antibiotic course merits specialist referral consideration.
03Possible toxicityRespond to a serious tetracycline symptomSevere headache or visual change, odynophagia, blistering, jaundice, severe diarrhoea or pregnancy occurs during treatment.+
- 1Stop or withhold the suspected medicine when clinically appropriate, assess urgency and obtain a precise exposure and symptom timeline.
- 2Arrange targeted examination and investigations for the suspected complication, including urgent eye or neurological assessment for intracranial-hypertension symptoms.
- 3Treat the adverse event, report it through the Yellow Card scheme when indicated and select future acne care without automatically substituting another antibiotic.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Lymecycline 408 mg capsules
Take one capsule orally once daily as the systemic component of an initial twelve-week acne regimen; swallow with adequate fluid and follow the dispensed product information.Avoid during pregnancy, breastfeeding and under 12 years; consider renal or hepatic disease, photosensitivity, intracranial-hypertension symptoms, isotretinoin and absorption interactions.
Doxycycline 100 mg capsules
Take 100 mg orally once daily for the planned acne course when this formulation and dose are selected; swallow with plenty of fluid while upright and follow product-specific food instructions.Avoid pregnancy, breastfeeding, age under 12 and isotretinoin overlap; discuss oesophagitis, photosensitivity, headache or visual symptoms and interactions with antacids or mineral supplements.
Adapalene 0.1% with benzoyl peroxide 2.5% gel
Apply a thin film to all clean, dry acne-affected skin once each evening, starting on alternate days or with short contact if irritation is expected.Contraindicated in pregnancy or pregnancy planning; avoid mucosa and damaged skin, manage irritancy, reduce excessive ultraviolet exposure and warn about textile bleaching.
Azelaic acid 20% cream
Apply a thin layer to affected skin twice daily after cleansing; approximately 2.5 cm of cream is sufficient for the whole facial area.Avoid eyes and mucosa, reduce to once daily or interrupt briefly for troublesome irritation, and reassess if there is no improvement after an adequate course.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Record at initiation the systemic indication, previous antibiotic exposure, companion non-antibiotic topical, exact course length and planned review date.
- Ask during treatment about swallowing pain, severe headache, visual symptoms, diarrhoea, rash, photosensitivity and pregnancy-status changes.
- At twelve weeks, compare inflammatory lesions, nodules, new scars, function and photographs when consented; do not extend solely for flat residual pigmentation.
- If the oral agent continues after partial response, prescribe only to the next defined review rather than authorising unmonitored repeats.
- For the exceptional course beyond six months, review at least every three months and document why benefit still outweighs resistance and adverse-effect harms.
- Reconcile prescriptions from dermatology, private or online services before every repeat so an unrecognised tetracycline–isotretinoin overlap cannot continue.
- When treatment is stopped for intolerance, document the adverse symptom, actual duration and recovery rather than recording the course as completed and ineffective.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
The companion topical outlives the capsule
A non-antibiotic field treatment controls microcomedones during systemic therapy and can remain after the antibiotic stops.
Residual colour is not treatment failure
Flat post-inflammatory hyperpigmentation can persist after inflammatory activity has cleared and does not justify prolonged antibacterial exposure.
One antibiotic mechanism at a time
Removing topical clindamycin when an oral tetracycline starts is a deliberate stewardship intervention, not therapeutic undertreatment.
Administration prevents harm
Adequate water and remaining upright reduce doxycycline contact with the oesophagus and the risk of ulceration.
Failure deserves escalation
A well-used oral-antibiotic combination that fails moderate-to-severe acne supplies useful evidence for dermatology referral and isotretinoin assessment.
08Common pitfallsFrequent interpretation and management errors.
- 01
Issuing serial three-month antibiotic repeats while the record contains no review of lesions, scars or adherence.
- 02
Using an oral tetracycline for closed comedones without a non-antibiotic topical that addresses follicular occlusion.
- 03
Leaving topical clindamycin active on the repeat list when systemic doxycycline is initiated.
- 04
Extending treatment because brown macules remain despite the absence of palpable inflammatory lesions.
- 05
Missing an isotretinoin overlap when medicines are supplied by separate primary and specialist services.